2026-01-13 - Analysis Report
**Johnson & Johnson (JNJ) Report Summary**

### Recent Stock Price Fluctuations

* Close: $209.72
* 5-day SMA: $206.43
* 20-day SMA: $207.69
* 60-day SMA: $200.29

### Alpha, Beta Analysis

| Year | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------|------|------|-------|------|-------|
| 2016-2018 | 6.0% | 16.8% | 3.0% | 0.7 | 310.9B |
| 2017-2019 | 18.0% | 16.8% | 1.0% | 0.7 | 351.4B |
| 2018-2020 | 19.0% | 16.8% | -2.0% | 0.7 | 379.2B |
| 2019-2021 | 32.0% | 10.7% | -12.0% | 0.6 | 412.2B |
| 2020-2022 | 8.0% | 13.8% | 10.0% | 0.5 | 425.6B |
| 2021-2023 | -18.0% | 13.8% | -19.0% | 0.3 | 377.6B |
| 2022-2024 | -30.0% | 13.8% | -50.0% | 0.2 | 348.4B |
| 2023-2025 | 30.0% | 13.8% | -32.0% | 0.1 | 498.6B |

### Divergence and Return Rate Comparison

* Return rate (rate) of provided data: 54.09%
* Return rate of comparison stock (VOO): 94.34%
* Divergence: -40.25% (simply the difference in cumulative return)

### Market Indicators and Analysis

* RSI: 58.19 (oversold)
* PPO: -0.20 (strong sell signal)
* MRI: 0.80 (medium investment risk)

### Recent News & Significant Events

* [2026-01-12] Why Johnson & Johnson stock is up today: new Rybrevant data and earnings ahead
* [2025-12-19] Jim Cramer Couldn’t Stop Gushing About Johnson & Johnson (JNJ)’s Cancer Drugs
* [2026-01-12] Johnson & Johnson $JNJ Shares Sold by Atwater Malick LLC
* [2026-01-12] Assessing Johnson & Johnson (JNJ) Valuation After Drug Pricing Deal And New Clinical Trial Results
* [2025-12-30] More Upside For JNJ Stock In 2026?
* [2026-01-09] J&J Agreement Brings 15 of 17 Pharma Companies Into Trump's Drug-Pricing Effort

### Analyst Opinions

Analyst Consensus:
* Key: Buy
* Mean (1=StrongBuy~5=Sell): 2.16 (~Buy)
* Opinions: 24
* Target Price (avg/high/low): $212.00 / $240.00 / $155.00

### Recent Earnings Analysis

| Date | EPS | Revenue |
|-----|----|---------|
| 2025-10-22 | 2.14 | $23.99B |
| 2025-07-24 | 2.3 | $23.74B |
| 2025-04-23 | 4.57 | $21.89B |
| 2024-10-23 | 1.12 | $22.47B |
| 2025-10-22 | 1.12 | $22.47B |

### Financial Information

**Revenue and Profitability**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2025-09-30 | $23.99B | 69.56% |
| 2025-06-30 | $23.74B | 67.87% |
| 2025-03-31 | $21.89B | 66.40% |
| 2024-12-31 | $22.52B | 68.35% |
| 2024-09-30 | $22.47B | 69.01% |

**Capital and Profitability**

| Quarter | Equity | ROE |
|---------|---------|-----|
| 2025-09-30 | $79.28B | 6.50% |
| 2025-06-30 | $78.47B | 7.06% |
| 2025-03-31 | $78.11B | 14.08% |
| 2024-12-31 | $71.49B | 4.80% |
| 2024-09-30 | $70.16B | 3.84% |

### Comprehensive Analysis

* Recent stock price fluctuations indicate a stable trend, but PPO indicates a strong sell signal.
* Market indicators suggest a medium investment risk (MRI: 0.80).
* Analyst consensus recommends a "buy" with a target price of $212.00.
* Recent earnings analysis shows stable revenue and profitability.
* Financial information indicates a stable trend in revenue and profit margin.
* Comprehensive analysis suggests a neutral view, considering the current market indicators and recent news/events.

**Disclaimer:** This report is for informational purposes only and does not constitute financial advice. Investment involves risk.